N. prodotti: 0
Totale ordine: € 0,00
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536
Online ISSN 1827-1758
Vatansever H. S. 1, Gumus B. 2, Aydogdu O. 3, Sivrikoz O. N. 4, Türköz-Uluer E. 1, Kivanç M. 1, Ateşçi Y. Z. 3, Bugdayci H. 4
1 Department of Histology and Embryology, Faculty of Medicine, Celal Bayar University Manisa, Turkey;
2 Department of Urology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey;
3 Department of Urology, Izmir University, Izmir, Turkey;
4 Department of Pathology, Faculty of Medicine, Sifa University, Izmir, Turkey
AIM: The aim of this paper was to investigate the possible effect of cancer stem cells (CSCs) and relationship with Wnt/β-catenin signaling pathway progressing of prostate cancer.
METHODS: Thirty men with a pathological diagnosis of benign prostate hyperplasia (BPH) (group 1, N.=10), prostate cancer with a gleason score of ≤6 (group 2, N.=10), and prostate cancer with a gleason score of >6 (group 3, N.=10) were included in the study. The patients’ groups were compared in terms of immunoreactivity strength of prostatic stem/progenitor cell surface markers including CD133 and CD117. We also compared the immunoreactivity of Wnt7a, a part of Wnt signaling pathway which has a potential role in the progression of several cancers including prostate cancer. The immunoreactivity of Frizzled 6 (Fzd 6) which is the receptor of Wnt family was also evaluated in all groups.
RESULTS: Immunohistochemical analyses demonstrated that although CD133 immunoreactivity was positive in all groups, immunoreactivity was significantly stronger in group 3 when compared to other groups. While CD117 immunoreactivity was negative in group 1 and 2, it was positive in group 3. Wnt7a immunoreactivity was weak in all groups and Fzd 6 immunoreactivity was stronger in group 1 and 3 when compared to group 2.
CONCLUSION: Our findings demonstrated that CSCs and Wnt signaling pathway have a potential role in the development and progression of prostate cancer.